Loss of Commonly Mutated Gene in Prostate Tumors May Be Potential Biomarker for Targeted Treatment

Loss of Commonly Mutated Gene in Prostate Tumors May Be Potential Biomarker for Targeted Treatment
A new research study found that the loss of CHD1, one of the most commonly mutated genes in prostate tumors, may be a potential biomarker for targeted prostate cancer therapy. In the study, "Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness," published in EMBO Reports, researchers showed that CDH1 is involved in DNA damage repair mechanisms, and its loss sensitizes human prostate cancer cells to different drugs, including PARP inhibitors like Lynparza (olaparib). The CHD1 gene is mutated in 15 to 27 percent of all prostate tumors, with mut
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *